Showing results (331-340 of 352) with videos related to
Sort By:
Pageof 36
JAMA Dermatology|November 27, 2024
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical TrialsApril W Armstrong, Mark Lebwohl, Richard B Warren, et al.JAMA Dermatology|May 18, 2017
Pediatric Psoriasis Comorbidity Screening GuidelinesEmily Osier, Audrey S Wang, Megha M Tollefson, et al.Journal of the American Academy of Dermatology|November 6, 2007
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasisMark Lebwohl, Jerry Bagel, Joel M Gelfand, et al.The Journal of Allergy and Clinical Immunology|October 20, 2025
Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studiesAna Maria Giménez-Arnau, Robert Szalewski, Michihiro Hide, et al.American Journal of Clinical Dermatology|August 3, 2005
Long-term efficacy and safety of tretinoin emollient cream 0.05% in the treatment of photodamaged facial skin: a two-year, randomized, placebo-controlled trialSewon Kang, Wilma Bergfeld, Alice B Gottlieb, et al.Journal of the American Academy of Dermatology|March 31, 2024
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trialLinda Stein Gold, David N Adam, Lorne Albrecht, et al.JAMA Dermatology|June 22, 2018
Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic ReviewAdam R Ford, Michael Siegel, Jerry Bagel, et al.Journal of the American Academy of Dermatology|March 18, 2024
Full Guidelines-From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritisWarren A James, Angela L Rosenberg, Jashin J Wu, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 9, 2017
Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10Alexandra Zanin-Zhorov, Jonathan M Weiss, Alissa Trzeciak, et al.Journal of the American Academy of Dermatology|January 10, 2021
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatmentsJoel M Gelfand, April W Armstrong, Stacie Bell, et al.Pageof 36